RecruitingPhase 1NCT07148050
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Studying Rhabdoid tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Seattle Children's Hospital
- Principal Investigator
- Colleen Annesley, MDSeattle Children's Hospital
- Intervention
- SC-CAR.GPC3xIL15.21 CAR T cells(biological)
- Enrollment
- 21 enrolled
- Eligibility
- 1-26 years · All sexes
- Timeline
- 2025 – 2044
Study locations (1)
- Seattle Children's Hospital, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07148050 on ClinicalTrials.gov